Today is a very exciting day for Mountain Valley MD!  This morning we announced that we are commencing husbandry animal trials under the supervision of The People's Republic of Bangladesh’s Ministry of Fisheries & Livestock for our injectable solubilized Ivermectin technology, Ivectosol™ 1%.  Working directly with the government of Bangladesh opens up significant opportunities for MVMD to fast track our commercialization efforts for this groundbreaking product.

We have also announced that we are finalizing production supply agreements with key Bangladesh pharmaceutical partners to produce our novel Ivectosol™ 1% product for use and distribution throughout Bangladesh and to also serve as a major production hub for broader global distribution.  Securing top quality pharmaceutical partners who are FDA an EU compliant within a competitive cost structure is critical to align with one of the core tenets of MVMD’s mission to ensure accessibility to our technology for even the most disadvantaged nations.

“We are very excited to be welcoming Mountain Valley MD to The People's Republic of Bangladesh and are proud that they have selected our country for important research projects and as a key production hub for its solubilized Ivectosol™ 1% product,” stated Bangladesh’s Foreign Minister H.E. Dr. A. K. Abdul Momen, M.P.

As outlined in the media release, MVMD’s Ivectosol™ 1%, a fully solubilized form of the anti-parasitic drug Ivermectin, will be tested in cattle, goat and poultry under the supervision of the Bangladesh Government's approved and authorized laboratories and research institutes.  The trials are scheduled to commence in early April, 2021 and are anticipated to take 30 days.  The trial results are scheduled to be reviewed and approved by the Ministry of Fisheries & Livestock and Ministry of Health and will enable MVMD to advance against immediate commercialization opportunities.

We’ve been extremely impressed by the speed and pace with which the Government of the People’s Republic of Bangladesh continues to provide our teams with incredible support for the testing and preparedness of an accelerated commercialization pathway for Ivectosol™ 1%.  

The market we are going after includes new applications such as poultry and duck that were not previously possible based on viscosity limitations of the generic Ivermectin drug – we are talking about an annual consumption market size of more than 67 billion animals across just cattle, swine, goats and poultry!

You can read the full media release on our website here:
https://www.mountainvalleymd.com/investor/media-releases

There are so many exciting projects that we are advancing at an unprecedented pace and I could not be prouder of our team and our key partners in Bangladesh.  Today’s news is a massive validation of our progress and ability to move quickly towards solving real health and wellness problems.

Thank you to all of you for your ongoing support of our transformational work!